Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “underperform” rating reaffirmed by Royal Bank Of Canada in a research report issued to clients and investors on Monday, Marketbeat.com reports. They currently have a $13.00 price objective on the stock, down from their previous price objective of $15.00. Royal Bank Of Canada’s price objective indicates a potential downside of 2.40% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. BidaskClub cut Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Citigroup Inc. cut Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and dropped their price target for the company from $32.00 to $19.00 in a research report on Wednesday, August 16th. Maxim Group restated a “hold” rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Vetr cut Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating and set a $31.74 price target on the stock. in a research report on Wednesday, July 12th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Five investment analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and a consensus price target of $27.87.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 4.35% on Monday, hitting $13.90. The stock had a trading volume of 6,260,247 shares. The company’s market cap is $14.12 billion. The stock has a 50 day moving average price of $16.31 and a 200-day moving average price of $24.86. Teva Pharmaceutical Industries Limited has a 12-month low of $13.26 and a 12-month high of $44.12.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the firm posted $1.25 EPS. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.21 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/30/royal-bank-of-canada-lowers-teva-pharmaceutical-industries-limited-teva-price-target-to-13-00.html.

A number of hedge funds have recently bought and sold shares of TEVA. Capital Research Global Investors lifted its stake in Teva Pharmaceutical Industries Limited by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. lifted its stake in Teva Pharmaceutical Industries Limited by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares in the last quarter. FMR LLC lifted its stake in Teva Pharmaceutical Industries Limited by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares in the last quarter. Capital World Investors lifted its stake in Teva Pharmaceutical Industries Limited by 41.9% in the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after buying an additional 3,268,200 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Teva Pharmaceutical Industries Limited by 32.3% in the 2nd quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after buying an additional 2,782,257 shares in the last quarter. 56.55% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.